AKT1 and neoplasm: Thus, inhibition of HSP90 destabilizes client proteins such as AKT and 3-phosphoinositide-dependent protein kinase-1 (PDK1)18, disrupting PAM signaling and sensitizing tumor cells to apoptosis.